|
POSITIONS:
1989-Present Attending
Baylor University Medical
Center Dallas, Texas
1993-Present Clinical Director
Neuromuscular Center
The Institute for Exercise
and Environmental Medicine
Texas
Health Presbyterian Hospital
Dallas, Texas
1989-Present Neurologist and Partner
Texas
Neurology, P.A.
Dallas, Texas
CLINICAL RESEARCH:
1996-1999 Co-Investigator, Multi-Center,
Double-Blinded, Placebo-Controlled
Study of Betaseron in the Treatment
of Secondary Progressive Multiple
Sclerosis, Berlex Laboratories
1997-1999 Co-Investigator, A Double-
Blind, Placebo-Controlled, Dose-
Determination, Safety, Tolerability,
and Efficacy Study of Intravenous
Antegren in Patients with Multiple
Sclerosis During an Acute Exacerbation,
Elan Pharmaceuticals
1999 Co-Investigator, An Open
Label, Safety and Pharmacokinetic
Drug Interaction Study of Intra-
venous Antegren and Intramuscular
Interferon Beta-1A in Subjects with
Multiple Sclerosis, Elan
Pharmaceuticals
1999-2000 Co-Investigator, A Randomized, Double-Blind,
Placebo-Controlled, Safety, Tolerability, and Dose Evaluation Study of
Intravenous Antegren (natalizumab) at Two Dose Levels Using Magnetic
Resonance Imaging in Subjects with Multiple Sclerosis,Elan Pharmaceuticals
2000-2002 Co-Investigator, A Multi-Center, Open-Label
Antegenicity and Safety Study of a Human Serum Albumin-Free Pre-Formulated
Solution of
AVONEX® (Interferon beta-
1a) Administered Intramuscu-
larly to Patients with Relapsing
Multiple Sclerosis, Biogen
2000-2001 Co-Investigator, A Multinational, Multicenter,
Randomized, Double-Blind, Placebo-Controlled Study to
Evaluate the Efficacy, Tolerability,
And Safety of 2 Doses (5mg and
50mg) of Glatiramer Acetate Orally
Administered in Relapsing Remitting
Multiple Sclerosis Patients, Teva
2001-2004 Co-Investigator, A Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group, Multicenter Study to
Determine
the Safety and Efficacy
Of
Natalizumab in Subjects with
Relapsing/Remitting MS, Biogen
2001-2005 Co-Investigator, A Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group, Multicenter Study to
Determine the Safety and
Efficacy
Of Natalizumab, When Added to
Avonex, in Subjects with
Relapsing/
Remitting MS, Bioge
2002-2003 Co-Investigator, A Phase II, Randomized,
Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy,
Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects
with Relapsing-Remitting MS, Bristol Myers Squibb
2003-2004 Co-Investigator, A Randomized, Double Blind,
Placebo-Controlled, Parallel Group, Safety Study of Natalizumab in
Combination with Glatiramer Acetate (GA) in Subjects with
Relapsing/Remitting MS, Biogen
2003-2005 Co-Investigator, A Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy
of NBI-5788 in Patients with Relapsing Multiple Sclerosis, Neurocrine
Biosciences
2003-2004 Co-Investigator, A Multicenter, Open-Label
Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of
Avonex® (Interferon beta-1a) Administered Intramuscularly to Patients with
Relapsing/Remitting Multiple Sclerosis, Biogen
2004-2005 Co-Investigator, An Open-Label, Multicenter
Extension Study to Evaluate the Safety, Tolerability, and Efficacy of
Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies
C-1801, C-1802, or C-1803, Biogen
2005-2006 Co-Investigator, A Phase II Randomized,
Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous
Daclizumab in Patients with Active,
Relapsing Forms of Multiple
Sclerosis, PDL Biopharma
2006 to
present Co-Investigator, A Multinational, Multicenter,
Randomized, Parallel-Group, Double-Blind, Study to Compare the Efficacy,
Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of
Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by
Subcutaneous Injection in Subjects with RRMS, Teva Neuroscience
2006 Co-Investigator An Open-Label, Multicenter,
Extension Study to Evaluate the Safety and Tolerability of Natalizumab
Following Re-Initiation Of Dosing in Multiple Sclerosis Subjects Who Have
Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation.
LICENSURE: 1985
The State of Texas
BOARD CERTIFICATION:
1990 Board Certification, American Board
Of Psychiatry and Neurology
1994 Board Certification, American Board
of Electrodiagnostic Medicine
1996
Board Certification, American Board
Of Psychiatry and Neurology,
added
Qualification in
Neurophysiology
HONORS:
Phi Kappa Phi-Honor Society
Outstanding Sophomore, College of
Medicine
SOCIETIES:
1986 American Academy of
Neurology
1989 American Medical Association
1989 Texas Medical Association
1989 Dallas County Medical Society
1994 American Association Of Electrodiagnostic
Medicine
PUBLICATIONS:
Martin, A.W. and Ringel, S.P.:
Neuromuscular Junction and Muscle Disease
Prognosis of Neurological Disorders-1992
Eds. Evans, Retal, New York, Oxford
Universal Press, pp. 359-374
Martin, A.W., Haller, R.G., Barohn, R.:
Metabolic Myopathies
Current Opinion in Rheumatology
1994, 6:552-558
rev. 1-2008 |
